Other OTC - Delayed Quote USD

NovAccess Global Inc. (XSNX)

0.0077 -0.0003 (-3.75%)
At close: April 19 at 12:26 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Dwain K. Morris-Irvin M.P.H., MPH, Ph.D. CEO & Director 155.43k -- 1968
Mr. Neil J. Laird Chief Financial Officer -- -- 1953
Dr. Christopher Wheeler Ph.D. President of Stemvax Therapeutics -- -- --

NovAccess Global Inc.

8584 E. Washington Street #127
Chagrin Falls, OH 44023
United States
213 642 9268 https://www.novaccessglobal.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
3

Description

NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.

Corporate Governance

NovAccess Global Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 13, 2024 - May 17, 2024
NovAccess Global Inc. Earnings Call

Related Tickers

ATRX Adhera Therapeutics, Inc.
0.0060
0.00%
 
ESLA Estrella Immunopharma, Inc.
1.0700
+4.90%
 
FRES Fresh2 Group Limited
0.3683
+10.07%
 
BLPH Bellerophon Therapeutics, Inc.
0.0544
-4.73%
 
NBSE NeuBase Therapeutics, Inc.
0.4300
+1.32%
 
AZTR Azitra, Inc.
0.1950
+2.74%
 
NLSP NLS Pharmaceutics Ltd.
0.1327
+0.15%
 
THAR Tharimmune, Inc.
0.3770
+1.54%
 
GRI GRI Bio, Inc.
0.5279
+2.43%
 
NAMS NewAmsterdam Pharma Company N.V.
19.93
+2.52%